Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

A Study of Retreatment With Rituximab in Patients With Rheumatoid Arthritis Receiving Background Methotrexate

Study:

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Retreatment With Rituximab in Subjects With Rheumatoid Arthritis Receiving Background Methotrexate

Rationale:

n/a

Purpose:

This is a Phase III, randomized, double-blind, placebo-controlled, multicenter study evaluating the efficacy of retreatment with rituximab in subjects with active rheumatoid arthritis (RA) who are receiving Methotrexate (MTX).

Study Status: Active, not recruiting

Recruiting:
n/a

Condition Intervention Phase
Rheumatoid Arthritis Drug: Rituximab Phase 3

Verified by Genentech October, 2006

Sponsored by: Genentech
Information provided by: Genentech
ClinicalTrials.gov identifier: NCT00266227

Study Type: Interventional

Study Design: Treatment

Cleveland Clinic Foundation - Rheumatic and Immunologic Diseases
Cleveland, Ohio 44195
United States

Ariella Kelman, M.D.., Study Director

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit ClinicalTrials.gov
  Information obtained from ClinicalTrials.gov on
Link to the current ClinicalTrials.gov record.

Cleveland Clinic Mobile Site